Pulmonary arterial hypertension (PAH) encompasses a group of clinical entities
characterized by sustained vasoconstriction and progressive vascular remodeling that act in …

Pulmonary arterial hypertension (PAH) is a devastating disorder characterized by abnormal
increased vasoconstriction and vascular remodelling. In this review we discuss the …

Pulmonary arterial hypertension (PAH) is a rare disorder characterized by progressive
obliteration of small pulmonary arteries that leads to elevated pulmonary arterial pressure …

A RECENT META-ANALYSIS of 16 clinical trials of prostacyclin analogs, endothelin receptor
antagonists, and phosphodiesterase type 5 inhibitors in severe pulmonary arterial …

Pulmonary arterial hypertension (PAH) is defined foremost by a distinct pulmonary vascular
pathophenotype that occurs as a result of dysregulated vascular cell proliferation, intimal …

In pulmonary arterial hypertension (PAH), progressive structural remodeling accounts for the
pulmonary vasculopathy including the obliteration of the lung vasculature that causes an …

Recent investigations have suggested that it might be possible to reverse the pathology of
pulmonary arterial hypertension (PAH), a disorder that can be rapidly progressive and fatal …

Pulmonary hypertension (PH) is a disease with multiple etiologies and is categorized into
five broad groups. Of these groups, pulmonary arterial hypertension (PAH) is the most …

Pulmonary hypertension (PH) is a devastating disease and its successful treatment remains
to be accomplished despite recent advances in pharmacotherapy. It has been proposed that …

Current treatment of pulmonary arterial hypertension, which includes the use of
prostacyclins, endothelin receptor antagonists, and phosphodiesterase type 5 inhibitors …